Identification of chloroquine resistance Pfcrt-K76T and determination of Pfmdr1-N86Y copy number by SYBR Green I qPCR  by Tajebe, Addimas et al.
208
Document heading                                                                            ©2015 by the Asian Pacific Journal of Tropical Biomedicine. All rights reserved.
Identification of chloroquine resistance Pfcrt-K76T and determination of Pfmdr1-N86Y copy number by 
SYBR Green I qPCR   
Addimas Tajebe1,2*, Mulugeta Aemero2, Kimani Francis3, Gabriel Magoma1
1Pan African University Institute for Basic Sciences Innovation and Technology JKUAT, P .O. Box 62000-00200 Nairobi, Kenya         
2University of Gondar, P. O. Box 196, Gondar, Ethiopia             
3Kenya Medical Research Institute, P. O. Box 54840-00200 Nairobi, Kenya  
Asian Pac J Trop Biomed 2015; 5(3): 208-220
Asian Pacific Journal of Tropical Biomedicine
journal homepage: www.elsevier.com/locate/apjtb
    *Corresponding author: Addimas Tajebe, University of Gondar, P. O. Box 196, 
Gondar, Ethiopia.
       E-mail: admasu499@gmail.com 
     Foundation Project: Supported by the Pan African University Institute of Basic 
Science Innovation and Technology (Grant No. 132).
1. Introduction
   Plasmodium falciparum (P. falciparum) has a potential for drug 
resistance after any drug introduction to treat malaria. The parasite 
evolves to a new evolutionary line against anti-malaria drugs. 
Combination drugs are effective for treating chloroquine resistance 
P. falciparum malaria, but the parasite could develop a resistance 
including combination regimens with or without artemisinin[1]. 
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Objective: To identify prevalence of chloroquine resistance point mutation at (Pfcrt, K76T) 
and (Pfmdr1, N86Y) copy number variation.
Methods: SYBR Green I based real time PCR was used. One hundred and thirty-three samples 
were analyzed for (Pfcrt, K76T) and (Pfmdr1,N86Y) copy number from dried blood spot. 
Parasite DNA was extracted using high pure DNA preparation kit. The amplification of DNA 
was done by using AccuPower 2× GreenStarTM qPCR Master mix. For quantification purpose 
a new primer pair was designed for 178 base pair template from complete genome sequence 
of Plasmodium falciparum strain 3D7 at NCBI. Absolute quantification method was used to 
determine the Pfmdr1-N86Y copy number variations. Standard curve was built from strain 
3D7 gDNA since it has single copy of Pfmdr1 per haploid genome. The known positive 
controls with single and multi-copy number of Pfmdr1 gene were included in each experiment. 
The copy number ratio of the samples to the standard calibrator was made to obtain the fold 
difference among the samples with respect to copy number variation.  
Results: Out of 133 samples 73 (54.89%) were confirmed as mutant (Pfcrt, 76T) and the 
remaining 60 (45.11%) were genotyped as wild type (Pfcrt, K76). The (Pfmdr1, N86Y) copy 
number variation was determined for 133 clinical samples. Out of these samples 61 (45.86%) 
had single copy and the remaining 72 (54.14%) had multi-copy numbers higher than 1.5 copies 
per genome. Thirty-four (25.56%) multi-copies were between 1.5 and 2.5 copies per genome 
while 38 (28.57%) were more than 2.5 copies per genome. The minimum and maximum 
copies per genome were 0.474 and 4.741, respectively.
Conclusions: The study showed high prevalence level and fixation of Pfcrt, 76T mutation after 
chloroquine withdrawal. The prevalence of Pfmdr1 copy number variant suggested that the 
presence of modulating factor for emergence of Plasmodium falciparum strains with higher 
copy numbers. However, the prevalence level was not statistically significant.
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Drug resistance malaria is a major challenge to control P. falciparum 
malaria in developing and low income countries particularly sub-
Saharan Africa. It is the leading cause of morbidity and mortality[2].  
   Structurally chloroquine is a 4-aminoquinoline which was 
introduced in the late 1940s. Chloroquine was used as a massive 
scale for malaria treatment and prophylaxis. Due to its efficacy, 
affordability and safety, chloroquine is a kind of standard treatment 
drug against malaria for a long time[3,4]. Chloroquine is one of the 
cheapest and safest drugs ever used for malaria treatment[5]. It has 
one of the longest half-lives among antimalarials with approximately 
60 d, which provides a chemoprophylactic effect during the drug 
elimination phase. It also exposes parasites to an extended time 
period after which chloroquine has fallen below the therapeutic 
concentration, which may select for drug-resistant parasites[4]. 
   There are two main mutations which characterize chloroquine 
resistance in P. falciparum such as the Pfcrt and Pfmdr1 mutations. 
The (Pfcrt, K76T) and (Pfmdr1, N86N) are the most well-known 
markers for chloroquine resistance P. falciparum. P. falciparum 
chloroquine resistance at digestive food vacuole membrane has 
an association with each other. Pfcrt, K76T mutation occurs first 
and then another mutation followed. The (Pfcrt, K76T) point 
mutation yields more resistance than other Pfcrt point mutation[6]. 
The association of K76T mutation with other mutations in Pfcrt 
gene gives different levels of chloroquine resistance[7]. The K76T 
mutation is selected first followed by its association with other 
mutations in Pfcrt gene. 
   The (Pfmdr1, N86Y) copy number and codon mutations are 
important factors for drug resistance P. falciparum. An increase in 
copy number of a gene enhances the level of drug resistance. The 
high copy number of a target gene found together with a codon 
mutation, and then the parasite possesses enhanced anti-malaria 
drug resistance level. A study showed that an increased Pfmdr1 copy 
number with wild type codon (N86) had mefloquine sensitivity. On 
the other hand, increased Pfmdr1 copy number with codon mutation 
(86Y) had a higher resistance level[8]. However, other recent studies 
showed that higher copy number of Pfmdr1 could cause resistance 
in mefloquine, artesunate and lumefantrine while low copy number 
was sensitive to in vitro test regardless of codon mutation[9]. Pfmdr1 
polymorphism showed no relationship in in vitro susceptibility of 
these drugs[10]. Pfmdr1 copy number variation is more frequent 
event than Pfmdr1 codon mutation[11]. 
   Strong association was reported between K76T and N86Y 
mutations for chloroquine resistance[6,12]. When (Pfcrt, K76T) 
and Pfmdr1 wild type (N86) occur together, the parasite shows 
resistance to chloroquine. On the other hand, when Pfcrt-K76T 
occurs with Pfmdr1 mutant type (86Y), the parasite shows 
resistance to chloroquine, but (Pfcrt, K76) and (Pfmd1, N86) do 
not have resistance to chloroquine. This implies that the presence 
of (Pfcrt, K76T) mutation is pre-condition for the Pfmdr1 parasite 
to develop multi-drug resistance property against chloroquine and 
also Pfmdr1 increases the level of chloroquine resistance having 
synergetic effect with (Pfcrt, K76T). High parasite population with 
(Pfcrt, K76T) mutation favours the emergence of (Pfmdr1, N86Y) 
mutation[13]. Chloroquine resistance reached at fixation stage 
after the development of resistance[14,15]. The fixed population of 
chloroquine resistant P. falciparum will be continued in areas where 
P. falciparum and Plasmodium vivax (P. vivax) are co-endemic[16].   
   Chloroquine, primaquine and quinine were the most popular 
anti-malarial drugs for malaria treatment in Ethiopia before 1998. 
The Federal Ministry of Health, Ethiopia in 2004 recommended 
the use of quinine tablets and injection to treat severe malaria. The 
widespread chloroquine treatment failure by P. falciparum in 1997–
1998 led to the introduction of sulfadoxine/pyrimethamine for the 
treatment of P. falciparum malaria. Sulfadoxine/pyrimethamine has 
been in use until the adoption of Coartem in 2004[17]. 
   After the banning of sulfadoxine/pyrimethamine, Coartem is 
recommended to treat complicated malaria and mixed infections. 
Since 2005 up to date chloroquine, artesunate, quinine and Coartem 
are in use to treat malaria[17,18]. Chloroquine is still in use to treat 
uncomplicated malaria particularly P. vivax[17,18].  
   In the study area P. falciparum is common Plasmodium species 
and self-treatment is also common, so there is a danger that parasites 
develop resistance to Coartem and chloroquine[18]. The treatment of 
malaria in Ethiopia is done by chloroquine and Coartem nationwide. 
Coartem is given for complicated malaria and chloroquine is given 
for uncomplicated malaria especially for P. vivax infections. The 
treatment of P. vivax by using chloroquine as first-line drug might 
increase the prevalence of chloroquine transporter gene point 
mutation and P. falciparum multi-drug resistance. Chloroquine is 
incompletely withdrawn from the study area. Hence the (Pfcrt, 
K76T) and (Pfmdr1, N86Y) mutation would have been fixed in P. 
falciparum population. The prevalence of chloroquine resistance 
molecular markers for P. falciparum has not been established in the 
study area. Therefore, the prevalence level of chloroquine resistance 
point mutation at (Pfcrt, K76T) and (Pfmdr1, N86Y) copy number 
variants were determined as critical factors for future malaria 
treatment in the study area. 
2. Method and materials
2.1. Description of the study area 
   The study was conducted in six health centres in Dembia District 
and one hospital in Gendawuha District. Dembia District is located 
at an altitude range of 1750 m to 2100 m above sea level; latitude 
and longitude of 12°36’N 37°28’E and 729 Km from the capital 
Addimas Tajebe et al./Asian Pac J Trop Biomed 2015; 5(3): 208-220210
Addis Ababa. Dembia district covers an area of 1270 km2 with a total 
population of about 263000. This area is endemic to malaria and P. 
falciparum and P. vivax are the most commonly reported species 
from microscope diagnosis of febrile patient. The hospital is located 
at Gendawuha District which is found in latitude and longitude of 
12°58’N 36°12’E with an elevation of 685 m above sea level and 
approximately 950 km from the capital Addis Ababa. The area has 
approximate population of 5502. The two areas have severe malaria 
transmission seasons such as October to December (Figure 1). 
2.2. Ethical clearance
   The research proposal was submitted to University of Gondar 
Natural and Computational Science College Ethical Review 
Committee for Ethics approval. The Committee approved the 
proposed research is ethically cleared after thorough consideration 
of the proposed research proposal. Consent form was prepared for 
study participants. The purpose of this study was explained for 
participants and parents/guardians in their mother tongue before 
being recorded in the study. Those who did not consent were not 
included in the study. In agreement with clinics and hospital the cost 
of drug for treating positive patients were covered by the clinics and 
hospital. 
2.3. Study design 
   The study was cross sectional. It was conducted during malaria 
transmission season (September to December, 2013). Malaria 
transmission is seasonal in Ethiopia, which is peak during autumn, 
September to December, and spring seasons, April to May. Six 
clinics (Tseda, Makisegnit, Chuahit, Aymba, Kola Diba and Sankisa) 
and one hospital (Metemma Hospital) were used as the study sites to 
collect samples from outpatients.
2.4. Study participants 
   Patients who attended the health institutions during study period 
were recruited for the study. Participants, who were between six 
months and seventy years old, were included in the study. Infants, 
under six months of age and pregnant women were excluded. 
Patients, who were reported as P. falciparum positive during health 
service, were asked for consent to participate in the study by health 
professionals. Finger pricks were done, by health professionals, for 
those patients who consented to participate in the study. 
2.5. Sampling 
   After finger pricking, two spots of blood samples were prepared on 
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Figure 1. Map of Ethiopia showing the study sites.
Addimas Tajebe et al./Asian Pac J Trop Biomed 2015; 5(3): 208-220 211
Whatman 3MM filter paper from each study participant. The blood 
spots were prepared by dropping three to four blood drops per spot 
on a piece of filter paper. In total, 168 blood samples were collected 
from all study sites (Tseda, n=14; Makisegnit, n=14; Sankisa, n=33, 
Chuahit, n=6; Kola Diba, n=32, Aymba, n=31; Metemma Hospital, 
n=38). The spots were properly labelled, air dried. Silica gel was 
added inside each plastic bag to prevent humidity. In order to avoid 
cross contamination one plastic bag was used for one filter paper. 
The cards were collected in sealed plastic bag and transported to 
Kenya Medical Research Institute for molecular analysis.
2.6. Parasite DNA extraction 
   A piece of dried blood spot of approximately 2-3 mm in size was 
cut out with sterile scissors. The pieces were placed in sterile 1.5 
mL extraction tubes using flamed forceps. High pure PCR template 
preparation kit (Version 20; Roche diagnostics, GmbH, Germany) 
was used to extract parasite DNA from dried blood spots. The 
extraction was done according to the manufacturer’s instructions. 
The extracted DNA was stored in -20 °C freezer until used for PCR. 
2.7. Real-time PCR condition and amplification 
   Real-time PCR is an advanced PCR type over convetional PCR. 
It is assisted by software for monitoring of the progress of DNA 
amplification. It does not depend on end product analysis. The 
progress of DNA amplification can be easily observed during the 
amplification reaction. In addition, real-time PCR is helpful for 
exclusion of primer-dimers and non-specific amplifications and, 
melting curve analysis is applied in real-time PCR. Real-time PCR 
helps to quantify the target gene and takes less time than convetional 
PCR. Therefore, in order to achieve the three objectives real-time 
PCR was used in the study.
   One step PCR was done using AccuPower 2× GreenStarTM qPCR 
Master mix in Exicycler 96 TM (Bioneer South Korea). ExicyclerTM 
Version 3.0 Software was used for programming the Exicycler 
Thermal Block (Exicycler 96) and data analysis was made based 
on operating manual from Bioneer. The reaction condition was 
done according to manufacturers’ instruction from the AccuPower 
2× GreenStarTM qPCR Master mix. It was done as first initiation 
step at 95 °C for 10 min; denaturation step at 95 °C for 20 seconds; 
combined annealing and extension at 55 °C for 30 seconds followed 
by scanning the amplification product. This one step PCR runs for 
continuous 40 cycles. The PCR products were immediately subjected 
for melting to generate melting curves. 
   The melting process occurs when double stranded DNA formed 
after PCR amplification is dissociated at high temperature and as it 
melts the SYBR Green I dye fluorescent gradually decreases because 
the dye no longer stays being attached to the double stranded DNA. 
This phenomenon detected by the Exicycler software and the software 
gave melting curves which had sharp turning point at the maximum 
melting temperature of each double stranded PCR amplification 
products. Therefore, each PCR product has specific “melting point” 
and hence temperature profiling is used for identification of PCR 
products.   
2.8. Melting curve analysis and primer-dimers
   Primer-dimers occur when two PCR primers either same sense 
primers or sense and anti-sense primers bind to each other instead 
of to the target. Melting curve analysis identified the presence of 
primer-dimers because PCR amplicon is usually higher in length 
than primer-dimers. Therefore it has higher “melting temperature” 
than primer-dimers. The presence of primer-dimers is not desirable 
in samples that contain template, as it decreases PCR efficiency and 
obscures analysis. The formation of primer-dimers most often occurs 
in no-template controls (NTCs), where there is an abundance of 
primers and no template. The presence of primer-dimers in the NTC 
served as an alert that they were also found in reactions that included 
template. If there were primer-dimers in the non-template control 
tube, the Ct values of the reactions were used for confirmation 
because Ct values of primer-dimers and Ct values of template were 
different. Primer-dimers have higher Ct values because primers 
are lower in concentration than template except the non-template 
control tube. Therefore, amplification curves with lower Ct values 
than NTC Ct value were taken as template reactions. Melting curve 
analysis of NTCs discriminated between primer-dimers and spurious 
amplification due to contaminating nucleic acids in the reagent 
components.
2.9. Real-time PCR amplification for (Pfcrt, K76T) 
identification 
   The amplification of (Pfcrt, K76T) gene was employed using 
published primer pairs CRT-F (5’-TGA CGA GCG TTA TAG 
AG-3’) and CRT-R (5’-GTT CTT TTA GCA AAA ATT G-3’)[19]. 
The amplification was done at 25 µL reaction volume. AccuPower 2x 
GreenStarTM qPCR Master mix (12.5 µL), 2 µL (10 pmole) forward 
primer, 2 µL (10 pmole) reverse primer, 3.5 µL DEPC-distilled water 
and 5 µL DNA template were used. NTC was included to control 
formation of primer-dimers. 
   Chloroquine resistant and sensitive P. falciparum strains (W2, D6 
and 3D7) obtained from Kenya medical research institute malaria 
laboratory were used as controls in order to identify wild type and 
mutant type clinical samples. These controls were included in each 
PCR run throughout the experiment. An artificial mix of DNA 
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extracted from these strains were made in different ratio in order to 
determine the efficiency and sensitivity of the assay to identify the 
wild type (Pfcrt, K76) and mutated type (Pfcrt, 76T) at different 
concentration levels. The ratios of strain W2 to strain D6 were (10 
µL:10 µL, 5 µL:10 µL) and strain W2 to strain 3D7 were (10 µL:10 
µL, 5 µL:10 µL). The mixing of the two strains was made to obtain 
the optimum detection threshold of the assay for genotyping (Pfcrt, 
K76T). The melting curves obtained from artificial mixed resistant 
strain with sensitive strain, and melting curves obtained from clinical 
samples were compared for confirmation purpose.
2.10. Melting curve analysis for (Pfcrt, K76T) identification
   Melting curve analysis is useful for identification of wild and 
mutant genotypes of (Pfcrt, K76T). Since the melting curve shapes 
and peaks are different in these two genotypes, the curve and 
specific temperature profile enable to discriminate K76 and 76T 
genotypes. Therefore, after amplification of the template DNA the 
PCR product was immediately subjected for melting at 70 °C to 
83 °C at ramping rate of 1.0 °C for 1 second. The known positive 
controls were included in order to identify the wild type and mutant 
type clinical samples. Chloroquine sensitive strains (D6, 3D7) and 
resistant strain (W2) were used as positive controls. NTC was also 
included for each run. The samples were identified as wild type 
and resistant type based on respective temperature profile and the 
shape of the melting curve graphs. The primary differential (F’) was 
selected from melting curve window for identification of the graph 
shape and peaks. The shape and peaks of the melting curves were 
carefully observed. The dual and single melting curve peaks were 
observed from 70 °C to 83 °C.
2.11. (Pfmdr1, N86Y) and copy number determination by 
qPCR
   Real-time PCR quantification of the target gene is better quantified 
when the template is short usually less than 200 bp. Therefore, in 
this study the Pfmdr1 amplification and copy number variation 
were determined from 178 bp long template DNA. In order to 
obtain short template newly designed primer pairs (forward 5’-GAT 
GGT AAC CTC AGT ACT-3’ and reverse 5’- CTC CTG ATA ATA 
CAG CAC-3’) were used with dual labelled single probe (5’-TET-
ACC TAA ATA CAT GTT CTT T-3’-BHQ1). The probe was used 
to differentiate the mutant and wild type of the samples at (Pfmdr1, 
N86Y) codon. The labelled probe complements to the codon 
mutation specific region of the (Pfmdr1, N86Y). Fluorescence can 
be detected from the complementation of the probe with template 
because the quencher and reporter dyes fluoresce only when there is 
complementation between the target and the probe sequences. The 
probe sequence was obtained from published paper[20].  
   In order to determine the copy number variation targeted in 
(Pfmdr1, N86Y) position, these newly designed qPCR primer pairs 
flanking in the complete mRNA (coding DNA sequence) regions of 
P. falciparum (3D7 strain) at chromosome five were used. Pfmdr1 
or Polyglycoprotein 1 is coded by the gene located at chromosome 
five in P. falciparum genome and is responsible for multidrug 
resistance development in P. falciparum. The 3D7 strain sequence 
was selected for primer design because this strain is fully sequenced 
and representative for P. falciparum genome study. Pfmdr1 develop 
due to functional Polyglycoprotein1, therefore, non-functional 
sequences were excluded during the primer design. 
   The FASTA sequence was browsed from NCBI (www.ncbi.nlm.
nih.gov/) at GenBank accession number (XM_001351751) and 
pasted in the Integrated DNA Technology Primer Quest (www.
idtdna.com). After copy-pasting the FASTA sequence format, the 
parameters such as primer length, product length, GC content, Tm 
of primer, Tm of product and salt concentration were adjusted from 
drop down menu of the software. After designing the new primer 
pair, it was analyzed for Tm mismatch, self-dimer formation (homo-
dimer), hairpin formation, and hetro-dimerization. The analysis was 
done by IDT Oligo analyser online (www.idtdna.com) and finally, 
“blastn” was done for the new primer pair from NCBI.  After these 
all process the primer pairs were validated to be used for absolute 
quantification of the target gene for copy number variation.
   The amplification of (Pfmdr1, N86Y) was done at 25 µL reaction 
volume of which 12.5 µL AccuPower 2× GreenStarTM qPCR Master 
mix, 2 µL (10 pmole) forward primer, 2 µL (10 pmole) reverse 
primer, 2 µL single probe, 1.5 µL DEPC-distilled water and 5 µL 
DNA template were used. Non-template control was included to 
control formation of primer-dimers. 
   Chloroquine resistant and sensitive P. falciparum strains (Dd2, 
W2, D6 and 3D7) obtained from Kenya medical research institute 
malaria laboratory were used as controls in order to determine copy 
number variation in clinical samples. These controls were included 
in each PCR run throughout the experiment in triplicated. 
2.12. Absolute quantification of Pfmdr1 (N86Y) copy number 
variation
   The standard curve was built from P. falciparum gDNA. The 
supporting manual from (www6.appliedbiosystems.com/support/
tutorials/pdf/quant_pcr.pdf) was obtained and used for preparation 
of the standard curve from strain 3D7 gDNA. P. falciparum (strain 
3D7) was used as reference copy number. This strain is known 
to have single copy of Pfmdr1 gene in the haploid P. falciparum 
genome. In order to build the standard curve the concentration 
of DNA extracted from 3D7 was measured by NanoDrop 2000 
spectrophotometer. The average concentration of the DNA was 
15.75 ng/µL which is equal to 15750 pg/µL. Absorbance of the 
DNA sample was measured at A260, A280, A260/280, A260/230. 
Derivation of DNA mass formula is as follows:
m=[n] =[n]
1 660 g g
bpmole
1.096 e-216.023e23 Moleculules (bp)[ [[] ] ]
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m=[n] g
bp
1.096 e-21[ ]
   Where n refers to genome size (bp), while m refers to mass.
   The Avogadro’s number is equal to 6.023×1023 molecules per 
mole and Average molecular weight of a double-stranded DNA 
molecule is 660 g/mole. The size of P. falciparum genome is around 
23 Mbp which is equal to 23000000 bp[21]. In order to obtain the 
mass of P. falciparum haploid genomic DNA from the whole 
genome size, 23000000 bp was inserted for n- value in the above 
formula. The mass of P. falciparum haploid genome is calculated as 
follows: 
m=[23×106 bp]
m=[0.025×10-15 g]
1.096×10-21 g
picogram
bp
g1×10
12
=0.025×10-15 g
=0.025 pg
[
[
]
]
   Dividing the mass of the haploid genome by the copy number of 
the gene of interest per haploid, genome gives the copy number of 
the gene in 0.025 pg. The 3D7 P. falciparum strain has the target 
gene that exists as a single copy gene per haploid genome (or two 
copies per P. falciparum cell). This implies that:
   0.025 pg One copy pfmdr1 0.025 pg÷ =Haploid genome Haploid gemone One copy of Pfmdr1
   Therefore, 0.025 pg of P. falciparum haploid genome contains 
one copy of Pfmdr1 (N86Y) gene. Then, calculations of the mass of 
gDNA containing the copy numbers of interests, which are 800000 
to 0.8 copies, were done. If one copy of Pfmdr1 gene is obtained 
from 0.025 pg of haploid genomic DNA, then 800000 copies of 
Pfmdr1 gene can be obtained from 20000 pg. 
   Copy number of interest×mass of haploid genome=mass of gDNA 
needed 
   The following calculation is used to obtain mass of haploid 
genomic DNA needed and the concentration of the DNA samples 
in five microliter template DNA in the ranges of copy numbers 
of interest from 800000 to 0.8 copies. The multiplication of copy 
number of interest by 0.025 pg gives the mass of haploid genome 
needed to get the concentration of DNA needed at five microliter 
template. The division of mass of haploid genome to five microliter 
DNA template gives final concentration of DNA for each dilution 
(Table 1). 
Table 1
Mass of genomic DNA needed and final concentration of input DNA (stock 
DNA) at five microliter template are calculated from copy number of 
interests.
Copy number 
of interest
Haploid 
genome of P. 
falciparum 
(pg)
Mass of needed 
(pg)
Volume of 
template 
(µL)
Final 
concentration 
(pg/µL)
800000
×0.025
20000
/5 
4000
80000 2000 400
8000 200 40
800 20 4
80 2 0.4
8 0.2 0.04
0.8 0.02 0.004
   Ten-fold serial dilution of the stock DNA was obtained by using 
the following formula based on the above concentration of template 
DNA. 
   C1V1=C2V2
Where: C1 refers to stock concentration (15750 pg/µL); V1 is 
required volume; V2 refers to 100 µL; C2 refers to 4000 pg/µL
   
V1= 
C2V2
C1
   Then the value of V1 is 25.4 µL. In order to obtain the 100 µL 
dilution a difference of 25.4 µL from 100µL diluent is needed. The 
volume of diluent is 74.6 µL. Ten-fold serial dilution was prepared 
from the stock DNA (Table 2) and standard curve was built from the 
diluted DNA sample.
Table 2
Serial dilutions from DNA stock solution.
Serial 
number
Initial concentration 
(pg/µL)
Volume 
1 (µL)
Final concentration 
(pg/µL)
Volume 2 
(µL)
Stock 15750 25.4 4000 100
1 4000 10 400 100
2 400 10 40 100
3 40 10 4 100
4 4 10 0.4 100
5 0.4 10 0.04 100
6 0.04 10 0.004 100
7 0.004 10 0.0004 100
   The standard was included in each run. The average amplification 
efficiency was 106% including at least three points from the 
serially diluted standard DNA template on the linear regression 
line. The PCR efficiency value is acceptable in the range 100+/-
10%. Outlier points were omitted from the reaction plate in order 
to get appropriate efficiency. The samples were laid on the linear 
regression line and there was no any outlier points omitted from 
the sample. There was no PCR efficiency difference between the 
standard and clinical samples, because the primer pairs were the 
same and designed for the same target (Pfmdr1, N86Y) region in 
the calibrator strain 3D7 and P. falciparum positive samples. Input 
DNA concentration was determined automatically for each sample 
by the Exicycler software based on the standard concentration. The 
following formula was used in order to calculate the copy number 
of samples from the concentration of the input DNA per microliter 
(www.scienceprimer.com).
DNA  copy number= [6.023×10
23 copy/mol]x[DNA amount(g/µl)]
[amplicon length(bp)]x[660g/mol×1/bp]
DNA  copy number= ×[DNA amount(g/µl)][ ]6.023×10
23  copy/mol
117480 g/mol
   The copy numbers were calculated using the above formula 
from DNA input concentration which was determined by the PCR.
Molecular weight of DNA is 660 g per mole per base pair and the 
amplicon length is 178 in base pair. Finally, the copy number ratio 
of positive controls (Dd2, W2 and D6) to 3D7 and samples to 3D7 
were calculated manually in order to obtain copy number variation 
or fold difference among the calibrator 3D7 strain, positive controls 
and clinical samples. In other words the ratio of input template 
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concentration of the samples and positive controls to the input 
template concentration of the 3D7 strain was determined. The ratio 
gives the fold difference between the sample and the reference strain 
3D7. The 3D7 strain has single copy of Pfmdr1 gene per haploid 
genome. Therefore, if the sample had more copies than 3D7 it would 
be considered as multi-copy. In contrast, if the sample had less or 
equal copy with 3D7, the sample would be considered as single. 
For instance, the copy number of 3D7 strain at 4000 pg/µL input 
concentration of DNA template was calculated as follows:
3D7 strain  DNA  copy number=
=2.05×1010 copies/µL
6.023× 4000×] ][ [ ( )10
23 copy
mol
pg
uL
[178 (bp)]× ×
660 g 1
mol bp ][
The ratio 3D7 to 3D7 >> 2.05×10
10
2.05×1010
3D7
3D7 = = 1 copy/µL
   The copy number of the positive control Dd2 strain at 694 pg/µL 
input concentration of DNA template was also calculated. Then, 
the ratio of Dd2 to 3D7 was obtained by dividing the copy number 
of Dd2 to copy number of 3D7 strain in order to get the fold 
difference between the two P. falciparum strains. 
  Dd2 strain DNA copy number=
=3.56×1010 copies/µL
6.023× 694×] ][ [ ( )10
23 copy
mol
pg
uL
[178(bp)]× ×
660 g 1
mol bp ][
The ratio Dd2 to 3D7=
3.56×1010
2.05×1010
Dd2
3D7 = 1.736 fold
   The remaining values for clinical samples are computed in the 
same way in order to get the copy number variations. 
3. Results
3.1. Pfcrt (K76T) identification and Pfmdr1 (N86Y) copy 
number determination
   In the study 133 samples were re-confirmed by SYBR Green 
I-based real-time PCR as P. falciparum positive samples. Those 
samples were analysed further for (Pfcrt, K76T) genotyping and 
(Pfmdr1, N86Y) copy number determination. 
   The P. falciparum chloroquine transporter gene was targeted for 
(Pfcrt, K76T) genotyping. The amplification of the target gene 
was recorded from log scale form of the amplification curves. This 
form of graph helps to exclude the non-specific amplifications, 
primer-dimers and other artefacts to the left bottom side of 
the graphs (Figure 2). The negative and positive controls were 
included in the experiment in each and every PCR runs.
   Melting curve analysis was made for (Pfcrt, K76T) genotyping. 
The shapes of the melting curves indicated the wild type (Pfcrt, 
K76) as flat curves and mutant type (Pfcrt, 76T) as raised curves 
with dual peaks. The strains (3D7 and D6) were positive controls 
for the wild type and showed flat curves and strain (W2) was 
Figure 2. Amplification of (Pfcrt, K76T) in log scale form.
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positive control for mutant type and showed raised melting curve 
with dual peaks (Figure 3).
   Among the 133 samples 73 (54.89%) were genotyped as 
resistant type (Pfcrt, 76T) and the remaining 60 (45.11%) were 
genotyped as wild type (Pfcrt, K76). In this study high prevalence 
of mutant genotype (Pfcrt, 76T) was found (Figure 4).
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Figure 4. The prevalence of (Pfcrt, K76T) point mutation.
3.2. Pfmdr1 (N86Y) amplification and copy number 
variation
   The genotyping of wild type (Pfmdr1, N86) and mutant type 
(Pfmdr1, 86Y) single amino acid polymorphs was done by using 
the dual labelled single probe, which was specifically designed to 
complement the mutant genotype (Pfmdr1, 86Y) codon mutation, 
and SYBR Green I dye. The yellow graphs generated by the TET-
labelled probe fluorescent were represented as mutant genotype 
(Pfmdr1, 86Y) and the green graphs generated by SYBR Green 
I dye were represented as wild type (Pfmdr1, N86) (Figure 5). 
The positive controls from resistant strains such as W2 and 
Dd2 were included and showed as yellow coloured graphs in 
the amplification graphs which were confirmed as positive for 
mutant genotypes in the assay throughout the experiment. In 
contrast, sensitive strains such as 3D7 and D6 showed as green in 
the amplification graph were confirmed as positive for wild type 
genotypes. Therefore, clinical samples were genotyped based on 
the positive controls and the colour of the graph. A few samples 
were categorized as the mutant genotype (Pfmdr1, 86Y) and the 
remaining of the samples were represented as wild type genotype 
(Pfmdr1, N86) (Figure 5). 
   The melting curve analysis was not successful for further 
analysis of these polymorphisms. The failure of melting curve 
analysis could be due to loose complementation between the 
probe and the template hence it melted rapidly before formation 
Figure 3. Melting curves for wild type and mutant type (Pfcrt, K76T) gene.
10k
0
Fl
uo
re
sc
en
ce
 in
te
ns
ity
           70           71           72            73           74            75           76           77           78            79           80            81           82            83         
Temperature
Negative samples
Autothreshold
10000
Std_SYBR_GREEN
W2(76T)
Addimas Tajebe et al./Asian Pac J Trop Biomed 2015; 5(3): 208-220216
of the sharp melt curve peaks.
   In order to determine the copy number of the target gene, 
the standard curve was made from a known concentration of 
genomic DNA which was serially diluted and having the same 
target gene with single copy per haploid genome. Then the input 
DNA concentration of each clinical sample was determined by 
the software automatically based on the concentration of serially 
diluted DNA from the standard curve (Figure 6). The blue points 
on the regression line represents the concentration of the standard 
sample. In other words, these points were obtained from the 3D7 
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Figure 5. Amplification curves of (Pfmdr1, N86Y) gene in log scale form.
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Figure 7. Copy number variation prevalence of (Pfmdr1, N86Y) gene.
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strain genomic DNA and the yellow points on the regression line 
represented the concentration of the clinical samples.
   A total of 133 samples were analysed further for determination 
of the (Pfmdr1, N86Y) copy number variation. Among the 
133 samples 73 (54.89%) samples were confirmed as multi-
copy variants of (Pfmdr1, N86Y) having copy numbers of the 
target gene from 1.5 copies to 4.471 copies per genome and the 
remaining 60 (45.11%) were confirmed as single copy variants 
of (Pfmdr1, N86Y) having copy numbers less than 1.5 copies per 
genome (Figure 7).
   The multi-copy number variants of (Pfmdr1, N86Y) were 
categorized as medium copy number variants and higher copy 
number variants. In this category 34 (25.56%) were medium copy 
number variants of (Pfmdr1, N86Y) having copy numbers less 
than 2.5 copies per genome and 38 (28.57%) were with higher 
copy number variants of (Pfmdr1, N86Y) having 2.5 copies or 
more copy numbers per genome (Figure 8). 
   The minimum and maximum copy numbers per genome were 
0.497 (single copy) and 4.741 (multi-copies), respectively. 
Positive controls obtained from Kenya medical research institute 
malaria laboratory were included in the assay. The controls were 
Dd2 P. falciparum strain which is known to have multiple copy 
numbers of (Pfmdr1, N86Y), and W2 and D6 P. falciparum strains 
which possess single copy number of (Pfmdr1, N86Y). The copy 
number variants of the positive controls were consistently found 
as single and multi-copy in each experimental runs.   
4. Discussion
   This is the first study conducted to determine prevalence of 
chloroquine transporter gene point mutations at (Pfcrt, K76T)
and (Pfmdr1, N86Y) copy number variation in the study area. 
The (Pfcrt, 76T) point mutation is the marker which shows the 
status of chloroquine resistant malaria. The high prevalence level 
of this mutation is an indicator for the spread of drug resistant 
P. falciparum population in the study area. There are no related 
data done for the prevalence level of chloroquine resistant malaria 
in the study area for comparison the result obtained from this 
study showed high prevalence of (Pfcrt, 76T) mutation, but not 
statistically significant (P>0.05). The (Pfcrt, 76T) point mutation 
is well established molecular marker for chloroquine resistance 
level and the prevalence rate of the resistant parasite (Pfcrt, 
76T) is the first mutation to be occurred and shows high level of 
resistance compared to the rest point mutations at Pfcrt gene[22]. 
Therefore, the higher the prevalence of this mutation, the more 
risk of malaria and challenging for drug resistance malaria control. 
In addition, high prevalence of (Pfcrt, 76T) suggests that the 
presence of drug pressure or other factors which favours (Pfcrt, 
76T) mutation. 
   Chloroquine was withdrawn from the study area since 2004 for 
treatment of P. falciparum malaria[17]. The parasite population 
with (Pfcrt, 76T) point mutation was expected that it would 
have been reduced. Change in chloroquine with other drug for 
P. falciparum treatment might disadvantage the mutant parasite 
survival. However, the parasite with mutant (76T) haplotype 
was fixed. The following reasons are contributing factors for 
fixation of (76T) mutation. The first is the incomplete withdrawal 
of chloroquine in the study area. Chloroquine is still in use for 
treatment of P. vivax. The second is high prevalence of mixed 
species infection. P. falciparum and P. vivax are endemic to 
the study area; therefore, mixed infection is common. The 
third is poor clinical diagnosis. The facilities and the skills of 
the laboratory technicians are critical for accurate detection of 
Plasmodium species. The fourth is poor management of malaria 
drugs. Patients purchase drugs from the shop and treat themselves 
without clinical diagnosis confirmation[18]. 
   If chloroquine was completely withdrawn, the parasite would 
have been reverted to (Pfcrt, K76) and chloroquine could be 
used for treatment of P. falciparum. Studies in Kenya, Tanzania 
and Malawi showed the conversion of (76T) to (K76) and 
reduction of (Pfcrt, 76T) prevalence[23,24]. The use of artemesinin 
combination therapy (ACT) increased throughout Africa[25]. 
Therefore, the prevalence of 76T point mutation was expected to 
be reduced in Africa. However, in Southern Ethiopia one study 
showed high prevalence of (Pfcrt, K76T) and (Pfmdr1, N86Y) 
point mutations[26]. The drug chloroquine could be used again as 
combination or single treatment drug to treat malaria caused by 
P. falciparum where chloroquine mutation prevalence is very low 
or disappeared[22]. The current study and another study done in 
Ethiopia showed a high prevalence level of chloroquine resistant 
P. falciparum point mutation and hence re-use of chloroquine for 
P. falciparum treatment in the Ethiopian context is not advisable. 
   Malaria parasite population dynamically evolves along with 
anti-malarial drug pressure. The change of treatment pressure 
or drug affects the parasite evolutionary process. The drugs of 
malaria can be reused after a long period of withdraw. Both Pfcrt 
and Pfmdr1 have synergic effect on chloroquine resistance level. 
The prevalence of P. falciparum with (76T) point mutation and 
high copy number variability at (Pfmdr1, N86Y) gene could 
trigger resistance for the new drug Coartem and impair the re-
introduction of the previous drugs in the study area. The high 
prevalence of (Pfcrt, 76T) point mutation with either (Pfmdr1, 
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N86) or (Pfmdr1, 86Y) high copy can affect the treatment of 
malaria.  
   In this study high prevalence of P. falciparum multidrug 
resistance    copy number variants were found, but it was not 
significant statistically (P>0.05). Copy number variation exists 
among P. falciparum strain regardless of codon mutation. 
Parasites do have coping mechanism against drug pressure and the 
mechanism is highly dynamic across P. falciparum population. 
When chloroquine was a treatment drug for P. falciparum 
the parasite was able to survive and become fully resistant to 
chloroquine. Codon mutation and/or copy number variation is/
are the most common means of resistance development against 
the most used treatment drugs. Studies showed that copy number 
variations occur first and the P. falciparum becomes tolerant for 
many drugs. The higher the copy numbers of (Pfmdr1, N86Y) 
gene is, the more tolerant against treatment drugs. Even the uses 
of combination drugs become risky for effective treatment. High 
population of multidrug resistance mutation and copy number 
variation in P. falciparum develop resistance for many drugs 
like mefloquinine, lumefantrine and/or artemisinin derivative 
combination drugs such as Coartem (artemether/lumefantrine).
   An in vitro study done in Ghana showed that nascent clones of 
P. falciparum manifested by reduced susceptibility to artemisinin 
derivatives[27]. Since lumefantrine and mefloquinine have 
physiochemical similarity, therefore, resistance to mefloquinine 
can be modulated by lumefantrine. A study done in Kenya 
showed that (Pfmdr1, N86Y) has association with mefloquinine 
response[28]. Another in vitro study in Cambodia-Thailand 
border showed that parasites with higher copy number showed 
significantly reduced susceptibility to mefloquinine, lumefantrine 
and artesunate. However, Pfmdr1 polymorphism showed no 
relationship in in vitro susceptibility of these drugs[10]. 
   Pfmdr1 copy number variation is more frequent event than 
Pfmdr1 codon mutation[11]. A knockdown study done on Pfmdr1 
gene copy number showed reduced susceptibility to mefloquinine, 
lumefantrine and artesunat in an in vitro susceptibility test. In 
contrast, this knockdown study showed that parasite line with 
low copy numbers had heightened susceptibility to artesunate and 
lumefantrine[9]. Parasites with single copy number are sensitive 
for mefloquinine, lumefantrine and artesunate. These drugs 
can be used for combination therapy where the population of P. 
falciparum with single copy number of Pfmdr1 gene are fixed[15].
   The study of copy number variation in P. falciparum population 
is very vital for monitoring of resistance malaria particularly 
where mefloquine and lumefantrine are used for combination 
therapy (ACT). Pfmdr1, are promising tools for the surveillance 
of drug resistance[29]. Pfmdr1 copy number is not only strongly 
associated with recrudescence to artesunate-mefloquine but also 
with Coartem failure[8].
   In the Ethiopian context Coartem is the treatment drug for 
uncomplicated malaria especially for P. falciparum. Since Coartem 
is an ACT drug which has lumefantrine component the presence 
of strains with high copy number variation in P. falciparum seems 
inevitable. The current study found high prevalence of multi-copy 
number variants in the study area. The parasite shifts from high 
Pfmdr1 copy number to low copy number or vice versa depending 
on the drug pressure in the parasite population. P. falciparum with 
higher copy number is spread and favoured when mefloquinine, 
mefloquinine combination or drugs physiochemical similarities to 
mefloquinine are used for treatment of P. falciparum. In contrast, 
P. falciparum population with higher copy shifts to population 
of parasites with low copy because withdrawal of mefloquinine 
pressure has fitness disadvantage for continuation of mefloquinine 
resistant P. falciparum[11]. 
   In this study a high prevalence of P. falciparum with a higher 
Pfmdr1 copy number variants were found. This showed that 
fixation of the P. falciparum population with fitness advantage 
with possessing multiple copy of (Pfmdr1, N86Y). It is, indirectly, 
an alert that there is drug pressure which favours these populations 
in the study area. The reasons could be incomplete withdrawal of 
chloroquine, use of lumefantrine combination drug (Coartem), 
misdiagnosis of single infections and mixed infections. It was 
found a high prevalence of mixed infection and misdiagnosed P. 
falciparum which would have been treated by undesired drug that 
could contribute for fixation of the resistant P. falciparum.   
   Although, it is not statistically significant, a high prevalence 
level of chloroquine resistant P. falciparum was obtained. The 
(Pfcrt, K76T) point mutation showed fixation of previous 
chloroquine resistant P. falciparum population after withdrawal of 
chloroquine in the study area. The prevalence of (Pfmdr1, N86Y) 
copy number variant was not  statistically significant, but it was 
highly spread and found to be an indicator of the evolutionary 
path shift from resistant P. falciparum for monotherapy to resistant 
P. falciparum population against combination drug therapy. 
Therefore, a high copy number variation is shown to be a risk 
factor for use of combination drugs for treatment of malaria. 
   Further, studies should be done to determine the prevalence 
level of P. falciparum chloroquine resistance point mutations 
and its fixation. It is critical for continuation or discontinuation 
of chloroquine use at a national level. Comprehensive molecular 
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surveillance is needed in order to control the spread of Pfmdr1 
copy number variants in P. falciparum population and it could be 
useful indicator of resistance development against combination 
therapy because Pfmdr1 copy numbers are increased when 
mefloquinine and related drugs are used for treatment of P. 
falciparum.
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Comments 
Background
   This study was conducted in the endemic area of P. falciparum 
where self-treatment is common, so it is danger that parasite 
develop resistance to Coartem and chloroquine (a first line drug). 
The (Pfcrt, K76T) and (Pfmdr1, N86N) are the most known 
markers for chloroquine resistance P. falciparum. Prevalence level 
of chloroquine resistance point mutation at (Pfcrt, K76T) and 
(Pfmdr1, N86Y) copy number variants were determined as marker 
for this study area.
  
Research frontiers
   The present research work depicts prevalence of chloroquine 
resistance point mutation at (Pfcrt ,K76T) and (Pfmdr1, N8Y)
copy number determination by using SYBR Green I qPCR. The 
method has been publish but this is the first report of prevalence of 
(Pfcrt, K76T) and (Pfmdr1, N86Y) in this area after chloroquine 
was withdrawn from this area.
Related reports
   There is another study report in 2014 for the first time the return 
of chloroquine sensitive P. falciparum in Southern and Eastern 
Ethiopia (not the same area of this study). The Pfcrt K76 CQ-
sensitive allele was observed in 84.1% of the investigated P. 
falciparum clinical isolates.
Innovations and breakthroughs
   The present study gives a chloroquine drug resistance 
surveillance report with drug resistance warning message for 
chloroquine drug pressure.
  
Applications
   This surveillance study has found the prevalence point mutation 
at (Pfcrt, K76T) and high copy number of Pfmdr1, N86Y in the 
study area. Although the result showed that it was not statistically 
significant. It might be alert that chloroquine was incompletely 
withdraw from this area and it could be a risk of drug resistance.    
Peer review
   This is the first study conducted to determine the chloroquine 
transporter gene point mutations at (Pfcrt, K76T) prevalence and 
(Pfmdr1, N86Y) copy number variation in the study area. In this 
study high prevalence of P. falciparum with a higher Pfmdr1 copy 
number variants were found. Surveillance studies to investigate 
resistance markers of Pfmdr1 and Pfcrt genes of P. falciparum 
in the same geographic area may help to assess the prevalence of 
antimalarial resistance.
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